Pharmacological inactivation of MYC for the treatment of cancer.
The overexpression of the MYC proto-oncogene has been implicated in the pathogenesis of most types of human cancer. Recent experimental observations indicate that the inactivation of MYC may be effective in the treatment of neoplasia. Several different strategies have been employed to develop novel drugs that may be effective to target the inactivation of MYC for the treatment of cancer. Some of these strategies are discussed.
Felsher
Dean W
DW
Division of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, California, USA. dfelsher@stanford.edu
Bradon
Nicole
N
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D016259:Genes, myc / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D000090063:Proto-Oncogene Mas; D014158:Transcription, Genetic / Q000187:drug effects
D000970:Antineoplastic Agents; C000715470:MAS1 protein, human; D016376:Oligonucleotides, Antisense; D000090063:Proto-Oncogene Mas